Anthony C Rongvaux

US Patent:

20110200982, Aug 18, 2011

Filed:

Oct 4, 2010

Appl. No.:

12/897517

Inventors:

Sean Stevens - San Diego CA, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Richard Flavell - Guilford CT, US
Elizabeth Eynon - New Haven CT, US
Jorge Galan - New Haven CT, US
Tim Willinger - New Haven CT, US
Markus Manz - Zurich, DE
Anthony Rongvaux - New Haven CT, US

International Classification:

C12Q 1/68
A01K 67/027
C12Q 1/70
C12Q 1/02

US Classification:

435 5, 800 9, 435 612, 435 29

Abstract:

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., or is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

US Patent:

20130022996, Jan 24, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/617472

Inventors:

SEAN STEVENS - San Diego CA, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Richard Flavell - Guilford CT, US
Elizabeth Eynon - New Haven CT, US
Jorge Galan - New Haven CT, US
Tim Willinger - New Haven CT, US
Markus Manz - Zurich, CH
Anthony Rongvaux - New Haven CT, US

International Classification:

A01K 67/027
G01N 33/566
C12Q 1/06

US Classification:

435 724, 800 9, 435 39

Abstract:

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., or is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

US Patent:

20130024957, Jan 24, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/617448

Inventors:

SEAN STEVENS - San Diego CA, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Richard Flavell - Guilford CT, US
Elizabeth Eynon - New Haven CT, US
Jorge Galan - New Haven CT, US
Tim Willinger - New Haven CT, US
Markus Manz - Zurich, CH
Anthony Rongvaux - New Haven CT, US

International Classification:

A01K 67/027
A61K 35/14
A61K 35/407
A61K 35/12

US Classification:

800 9, 424 937, 424 9372, 424 9371

Abstract:

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., or is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

US Patent:

20190297862, Oct 3, 2019

Filed:

Mar 13, 2019

Appl. No.:

16/352674

Inventors:

- Tarrytown NY, US
- New Haven CT, US
- Bellinzona, CH
Elizabeth Eynon - New Haven CT, US
Jorge Galan - New Haven CT, US
Tim Willinger - Ultran, SE
Markus Manz - Zollikon, CH
Anthony Rongvaux - New Haven CT, US
George D. Yancopoulos - Yorktown Heights NY, US

International Classification:

A01K 67/027
C07K 14/54
C07K 14/715
C12N 9/00
C07K 14/52
A61K 49/00
C07K 14/535

Abstract:

A mouse with a humanization of the miL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., or is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

US Patent:

20170172121, Jun 22, 2017

Filed:

Jan 3, 2017

Appl. No.:

15/397628

Inventors:

- Tarrytown NY, US
- New Haven CT, US
- Bellinzona, CH
Elizabeth Eynon - New Haven CT, US
Jorge Galan - New Haven CT, US
Tim Willinger - Ultran, SE
Markus Manz - Zollikon, CH
Anthony Rongvaux - New Haven CT, US
George D. Yancopoulos - Yorktown Heights NY, US

International Classification:

A01K 67/027

Abstract:

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mll2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/ll2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., or is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

US Patent:

20140090095, Mar 27, 2014

Filed:

Oct 14, 2013

Appl. No.:

14/053182

Inventors:

- Tarrytown NY, US
- Bellinzona, CH
- New Haven CT, US
Elizabeth Eynon - New Haven CT, US
Jorge Galan - New Haven CT, US
Tim Willinger - New Haven CT, US
Markus Manz - Zurich, CH
Anthony Rongvaux - New Haven CT, US
George D. Yancopoulos - Yorktown Heights NY, US

International Classification:

A01K 67/027
A61K 49/00

US Classification:

800 3, 800 11

Abstract:

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., or is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.